

PI Major Mutations:

[I54V](#) • [V82A](#) • [L90M](#)

PI Accessory Mutations:

None

PR Other Mutations:

L10I • K14R • R41K • D60E • L63P • I64V • A71V • I93L

Protease Inhibitors	
atazanavir/r (ATV/r)	High-Level Resistance
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	High-Level Resistance
indinavir/r (IDV/r)	High-Level Resistance
lopinavir/r (LPV/r)	High-Level Resistance
nelfinavir (NFV)	High-Level Resistance
saquinavir/r (SQV/r)	High-Level Resistance
tipranavir/r (TPV/r)	Low-Level Resistance

PR comments

Major

- I54V** is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV.
- V82A** is a non-polymorphic mutation selected primarily by IDV and LPV. It is associated with reduced susceptibility to LPV and to a lesser extent ATV. It increases DRV susceptibility.
- L90M** is a non-polymorphic PI-selected mutation that reduces susceptibility to ATV and to a lesser extent LPV.

Other

- L10I/V** are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- A71V/T** are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Drug resistance mutation scores of PI:

Download CSV

Rule	ATV/r ÷	DRV/r ÷	FPV/r ÷	IDV/r ÷	LPV/r ÷	NFV ÷	SQV/r ÷	TPV/r ÷
<a href="#">I54V</a>	15	0	10	15	15	20	15	20
<a href="#">I54V</a> + <a href="#">V82A</a>	10	0	10	10	10	10	10	0
<a href="#">I54V</a> + <a href="#">L90M</a>	10	0	10	10	5	10	10	0
<a href="#">V82A</a>	15	0	15	30	30	30	15	0
<a href="#">V82A</a> + <a href="#">L90M</a>	10	0	10	10	5	10	10	0
<a href="#">L90M</a>	25	0	20	30	15	60	45	0
Total	85	0	75	105	80	140	105	20

NRTI Mutations:

[D67N](#) • [K70R](#) • [T215F](#) • [K219Q](#)

NNRTI Mutations:

None

RT Other Mutations:

K32N • T39A • A98AS • D121Y • K122E • I135K • K173Q • I178L • V245Q

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Intermediate Resistance	doravirine (DOR)	Susceptible
zidovudine (AZT)	High-Level Resistance	efavirenz (EFV)	Susceptible
stavudine (D4T)	High-Level Resistance	etravirine (ETR)	Susceptible
didanosine (DDI)	Intermediate Resistance	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Potential Low-Level Resistance	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Potential Low-Level Resistance		
tenofovir (TDF)	Intermediate Resistance		

RT comments

NRTI

- D67N** is a non-polymorphic TAM associated with low-level resistance to AZT.
- K70R** is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs.
- T215Y/F** are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.
- K219E/Q/N/R** are accessory TAMs that usually occur in combination with multiple other TAMs.

Drug resistance mutation scores of NRTI: [Download CSV](#)

Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF
<u>D67N</u>	5	15	15	5	0	0	5
<u>D67N + K70R + K219Q</u>	10	15	10	10	10	10	10
<u>D67N + T215F + K219Q</u>	5	5	5	5	0	0	5
<u>K70R</u>	5	30	15	10	0	0	5
<u>T215F</u>	10	60	40	15	0	0	10
<u>K219Q</u>	5	10	10	5	0	0	5
<u>K70R + T215F</u>	0	0	5	5	0	0	0
Total	40	135	100	55	10	10	40

No drug resistance mutations were found for NNRTI.